Page 137 - Read Online

Page 10 of 11 Fatourou et al. Hepatoma Res 2018;4:63 I http://dx.doi.org/10.20517/2394-5079.2018.62

2. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the
Liver. EASL practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
3. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver
transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
4. Lerut J, Lai Q. Morphology does not tell us the entire story: biological behavior improves our ability to select patients with hepatocellular
carcinoma waiting for liver transplantation. Hepatobiliary Pancreat Dis Int 2015;14:570-1.
5. Lai Q, Iesari S, Melandro F, Mennini G, Rossi M, Lerut J. The growing impact of alpha-fetoprotein in the field of liver transplantation for
hepatocellular cancer: time for a revolution. Transl Gastroenterol Hepatol 2017;2:72.
6. Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, Toso C. The impact of waiting list alpha-fetoprotein changes on the
outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011;55:814-9.
7. Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, Fan J, Cescon M, Di Sandro S, Yi-Feng H, Lauterio A, Bongini M, Cucchetti A.
Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology
2018;154:128-39.
8. Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY.
Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver
transplant. JAMA Oncol 2017;3:493-500.
9. Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, Kneteman NM. Total tumor volume and alpha-fetoprotein for
selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology 2015;62:158-65.
10. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J,
Dharancy S, Gugenheim J, Bernard PH, Adam R, Radenne S, Muscari F, Conti F, Hardwigsen J, Pageaux GP, Chazouilleres O, Salame
E, Hilleret MN, Lebray P, Abergel A, Debette-Gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D. Liver transplantation for
hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012;143:986-
94.
11. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver
transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl 2014;20:945-51.
12. Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone G, Goffette P, Vogel W, Pitton MB, Lerut J. Alpha-fetoprotein and modified
response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and
death after transplantation. Liver Transpl 2013;19:1108-18.
13. Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence
using the UNOS database. Am J Transplant 2018;18:1206-13.
14. Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR. Systematic review: the prognostic role of alpha-fetoprotein following liver
transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2012;35:987-99.
15. Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular
carcinoma. Liver Transpl 2013;19:634-45.
16. Lai Q, Avolio AW, Manzia TM, Sorge R, Agnes S, Tisone G, Berloco PB, Rossi M. Combination of biological and morphological
parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation. Clin Transplant 2012;26:E125-31.
17. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, Lemoine A, Bismuth H, Castaing D, Adam R. Progression of
alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant
2010;10:129-37.
18. Lai Q, Vitale A, Iesari S, Finkenstedt A, Mennini G, Spoletini G, Hoppe-Lotichius M, Vennarecci G, Manzia TM, Nicolini D, Avolio AW,
Frigo AC, Graziadei I, Rossi M, Tsochatzis E, Otto G, Ettorre GM, Tisone G, Vivarelli M, Agnes S, Cillo U, Lerut J. Intention-to-treat
survival benefit of liver transplantation in patients with hepatocellular cancer. Hepatology 2017;66:1910-19.
19. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular
carcinoma utilizing the scientific registry of transplant recipients database. Hepatology 2009;49:832-8.
20. Ciccarelli O, Lai Q, Goffette P, Finet P, De Reyck C, Roggen F, Sempoux C, Doffagne E, Reding R, Lerut J. Liver transplantation for
hepatocellular cancer: UCL experience in 137 adult cirrhotic patients. Alpha-foetoprotein level and locoregional treatment as refined
selection criteria. Transpl Int 2012;25:867-75.
21. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM. Liver transplantation for hepatocellular carcinoma: Hangzhou
experiences. Transplantation 2008;85:1726-32.
22. McHugh PP, Gilbert J, Vera S, Koch A, Ranjan D, Gedaly R. Alpha-fetoprotein and tumour size are associated with microvascular invasion
in explanted livers of patients undergoing transplantation with hepatocellular carcinoma. HPB (Oxford) 2010;12:56-61.
23. Grat M, Wronka KM, Stypulkowski J, Bik E, Krasnodebski M, Masior L, Lewandowski Z, Grat K, Patkowski W, Krawczyk M. The
Warsaw proposal for the use of extended selection criteria in liver transplantation for hepatocellular cancer. Ann Surg Oncol 2017;24:526-
34.
24. Lee HW, Song GW, Lee SG, Kim JM, Joh JW, Han DH, Kim SI, Kim SH, Kim DS, Cho JY, Suh KS. Patient selection by tumor markers in
liver transplantation for advanced hepatocellular carcinoma. Liver Transpl 2018; doi: 10.1002/lt.25056.
25. She WH, Chan ACY, Cheung TT, Lo CM, Chok KSH. Survival outcomes of liver transplantation for hepatocellular carcinoma in patients
with normal, high and very high preoperative alpha-fetoprotein levels. World J Hepatol 2018;10:308-18.
26. Notarpaolo A, Layese R, Magistri P, Gambato M, Colledan M, Magini G, Miglioresi L, Vitale A, Vennarecci G, Ambrosio CD, Burra P,
Di Benedetto F, Fagiuoli S, Colasanti M, Maria Ettorre G, Andreoli A, Cillo U, Laurent A, Katsahian S, Audureau E, Roudot-Thoraval F,
Duvoux C. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received
a liver transplant for HCC. J Hepatol 2017;66:552-59.
27. Pinero F, Tisi Bana M, de Ataide EC, Hoyos Duque S, Marciano S, Varon A, Anders M, Zerega A, Menendez J, Zapata R, Munoz L,